Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.80M | 12.43M | 13.28M | 12.98M | 13.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.80M | 12.43M | 13.28M | 12.98M | 13.95M |
| Cost of Revenue | 5.69M | 5.64M | 5.84M | 5.31M | 5.66M |
| Gross Profit | 7.11M | 6.79M | 7.44M | 7.67M | 8.29M |
| SG&A Expenses | 7.82M | 7.63M | 7.61M | 7.50M | 7.65M |
| Depreciation & Amortization | 1.02M | 1.07M | 1.12M | 1.12M | 1.12M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.05M | 14.85M | 15.11M | 14.43M | 14.90M |
| Operating Income | -2.25M | -2.42M | -1.82M | -1.46M | -950.90K |
| Income Before Tax | -1.87M | -2.06M | -1.53M | -1.14M | -644.40K |
| Income Tax Expenses | 144.80K | 144.80K | 214.00K | 336.70K | -145.50K |
| Earnings from Continuing Operations | -2.01 | -2.21 | -1.74 | -1.48 | -0.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.01M | -2.21M | -1.74M | -1.48M | -498.90K |
| EBIT | -2.25M | -2.42M | -1.82M | -1.46M | -950.90K |
| EBITDA | -1.31M | -1.43M | -775.30K | -415.90K | 86.30K |
| EPS Basic | -0.10 | -0.11 | -0.09 | -0.07 | -0.02 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.05 | -0.03 | -0.02 |
| EPS Diluted | -0.11 | -0.11 | -0.09 | -0.07 | -0.02 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.05 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 78.30M | 79.39M | 80.28M | 81.02M | 81.43M |
| Average Diluted Shares Outstanding | 78.30M | 79.39M | 80.28M | 81.02M | 81.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
